Elsie DiBella, Ph.D.
Vice President of Manufacturing and Development
Dr. DiBella has served as our Vice President of Manufacturing and Development since March 2021. Dr. DiBella has over 20 years of industry experience in biologics development and manufacturing. Dr. DiBella has worked on over 20 biologics from the preclinical stage through post-approval changes. Prior to joining ContraFect, Dr. DiBella was the Head of Biologics Process and Analytical Development at what was Momenta Pharmaceutical overseeing a portfolio of both novel and biosimilar biologics. Previously, Dr. DiBella held roles of increasing responsibility with Process Development and Manufacturing Sciences at Shire Pharmaceuticals, Centocor Pharmaceuticals and Bristol-Myers Squibb. While at Shire Pharmaceuticals, Dr. DiBella held leadership roles in Process Development and in Manufacturing Sciences and contributed to the BLA, sBLA and global marketing authorization submissions for VPRIV, marketing authorization for Replagal AF in Europe and Japan and global approvals for Elaprase in addition to numerous INDs/CTAs for clinical stage programs. While at Centocor Pharmaceuticals, Dr. DiBella was responsible for the late-stage purification process development of and contributed to the BLAs for Simponi and Stelara.
Dr. DiBella received her B.S. in Chemistry from Bates College and her Ph.D. in Biophysical Chemistry from Cornell University in the laboratory of Harold Scheraga.